The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Docetaxel in the treatment of metastatic hormone-sensitive and castration-resistant prostate cancer: A meta-analysis.
 
Shijia Zhang
No Relationships to Disclose
 
Larysa Jessica Sanchez
No Relationships to Disclose
 
Jieqi Liu
No Relationships to Disclose
 
Yucai Wang
No Relationships to Disclose
 
Narjust Duma
No Relationships to Disclose
 
Victor Tsu-Shih Chang
Stock and Other Ownership Interests - Johnson & Johnson
 
Robert S. Alter
Consulting or Advisory Role - Algeta/Bayer; Astellas Pharma; Medivation; Sanofi
Speakers' Bureau - Algeta/Bayer; Amgen; Astellas Pharma; Dendreon; Janssen Oncology; Pfizer; Teva
 
Martin Gutierrez
Stock and Other Ownership Interests - COTA
Consulting or Advisory Role - Bayer; Lilly
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Abbvie (Inst); Acceleron Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Esanex (Inst); Gilead Sciences (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Rexahn Pharmaceuticals (Inst); TG Therapeutics (Inst)
 
A. Oliver Sartor
Consulting or Advisory Role - Algeta ASA; Aragon Pharmaceuticals; Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Biscayne Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Pfizer; Sanofi
Research Funding - Algeta ASA (Inst); Bayer (Inst); Johnson & Johnson (Inst); Progenics (Inst); Sanofi (Inst); Takeda (Inst)